✦ LIBER ✦

Spleen Tyrosine Kinase Inhibitors for Rheumatoid Arthritis: Where Are We Now?

✍ Scribed by Scott, Ian C.; Scott, David L.

Book ID: 125386845
Publisher: Springer International Publishing AG
Year: 2014
Tongue: English
Weight: 230 KB
Volume: 74
Category: Article
ISSN: 0012-6667
DOI: 10.1007/s40265-014-0193-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An Oral Spleen Tyrosine Kinase (Syk) Inh

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

✍ Weinblatt, Michael E.; Kavanaugh, Arthur; Genovese, Mark C.; Musser, Theresa K.; 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 256 KB

Inhibition of Spleen Tyrosine Kinase for

Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis

✍ Aarat M. Patel; Daniel Lupash; Douglas Chew; Marc C. Levesque; Larry W. Moreland 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 52 KB

Tolerogenic dendritic cell therapy for r

Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

✍ Hilkens, C. M. U.; Isaacs, J. D. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

Role of Spleen Tyrosine Kinase Inhibitor

Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis

✍ Professor David L. Scott 📂 Article 📅 2011 🏛 Springer International Publishing AG 🌐 English ⚖ 156 KB

Bruton's tyrosine kinase inhibitors for

Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

✍ Whang, Jennifer A.; Chang, Betty Y. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Access to tumour necrosis factor inhibit

Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?

✍ C. Y. Lu; K. M. Williams; R. O. Day 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 607 KB